Phase 3 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with severe or moderate congenital hemophilia A (a hereditary bleeding disorder caused by low levels of a clotting protein called Factor VIII)
- You do not currently have "inhibitors" — meaning your body has not developed antibodies that block the clotting treatment from working
- A test taken within the last 12 months has confirmed no inhibitors were present in your blood
- You have detailed records of your bleeding episodes and hemophilia treatments from at least the past 6 months
- If you are someone who could become pregnant, you agree to follow the contraception requirements set out by the trial
Who may not be able to join:
- You have a known allergy or sensitivity to any of the study treatments or their ingredients, or any other allergy that the trial doctor feels makes participation unsafe
- You are currently taking, or plan to take, certain medicines that affect your immune system (such as interferon or rituximab) — though HIV antiviral treatments are generally an exception (confirm with trial site)
- You are planning to have surgery during the trial, apart from very minor procedures like a simple tooth extraction or a small skin procedure
- You have a history of, or currently have, certain significant heart rhythm or electrical problems detected by a heart tracing (ECG), or a history of a heart attack
- You are unwilling to receive blood or plasma products in an emergency situation
- You have a history of, or risk factors for, serious irregular heart rhythms — for example, significant heart muscle problems or coronary (heart) disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. Only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment Period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.